The company said Concannon will remain with Haemonetics through the end of October to “ensure a seamless transition,” while the board searches for a permanent replacement.
“Ron’s intimate familiarity with Haemonetics’ business and vision, his decades of experience in the healthcare industry, and proven leadership track record make him an ideal and natural choice for Interim CEO. Haemonetics has an incredibly deep bench of talent, and Ron’s expertise and guidance will support our efforts to usher in a new phase of growth. I’d like to thank Brian for his contributions over the past 12 years, and we wish him the best in his future endeavors,” board chair Richard Meelia said in prepared remarks.
Concannon joined Haemonetics in 2003 to head its patient division and was promoted to COO in 2007 and CEO in 2009.
“During my 15 years as a member of its board, I have had the privilege of supporting Haemonetics’ evolution, and I am looking forward to leveraging my industry experience as I work with this world-class team in this new capacity. I am fully committed to ensuring a completely seamless transition and continuity in leadership as we work to identify and onboard a permanent replacement for the CEO role,” Gelbman said in a press release.
Evolent Health CAO Cann steps down
Evolent Health said last week its chief accounting officer Cynthia Cann has resigned and will be replaced by Lydia Stone, who will serve as interim CAO. Cann will stay on to consult with Evolent through the end of the 3rd quarter, the company said.
Voalte lures Siemens exec Friel
Sarasota, Fla.-based mobile healthcare communication company Voalte said it tapped ex-Siemens Healthcare HIT veep Sean Friel as its new senior veep of sales and marketing.
Baxter appoints Third Point’s Islam to board, inks voting, board deal
Baxter (NYSE:BAX) said it appointed investment advisory firm Third Point‘s Munib Islam to its board, as well as an unnamed independent director. The company also inked a deal with Third Point that includes standstill and voting provisions and a commitment to declassify the company’s board.